Newron Pharmaceuticals Income Statement

Financials in millions EUR. Fiscal year is January - December.

Millions EUR. Fiscal year is Jan - Dec.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Jun '25 Jun 30, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021	Dec '20 Dec 31, 2020
Operating Revenue	59.54	51.39	6.79	5.95	5.76	5.26
Other Revenue	0.35	-	2.26	0.14	-	-
Revenue	59.88	51.39	9.06	6.09	5.76	5.26
Revenue Growth (YoY)	759.13%	467.41%	48.62%	5.76%	9.59%	-25.29%
Gross Profit	59.88	51.39	9.06	6.09	5.76	5.26
Selling, General & Admin	11.41	11.58	7.53	7.39	7.39	8.47
Research & Development	13.27	13.64	13.15	12.01	10.73	14.85
Operating Expenses	24.68	25.22	20.69	19.4	18.12	23.32
Operating Income	35.2	26.17	-11.63	-13.3	-12.36	-18.07
Interest Expense	-4.4	-4.35	-4.17	-3.95	-2.92	-2.24
Interest & Investment Income	0.4	0.14	0.18	0.06	0.05	0.06
Currency Exchange Gain (Loss)	-0.11	-0.1	-0.07	0.12	0.2	-0.17
Other Non Operating Income (Expenses)	-0.21	-0.47	-0.51	-0.4	0.13	0.79
EBT Excluding Unusual Items	30.88	21.39	-16.2	-17.47	-14.88	-19.62
Pretax Income	30.88	21.39	-16.2	-17.47	-14.88	-19.62
Income Tax Expense	5.55	5.55	0.02	0.02	0.02	1.38
Net Income	25.33	15.84	-16.22	-17.49	-14.9	-21
Net Income to Common	25.33	15.84	-16.22	-17.49	-14.9	-21
Shares Outstanding (Basic)	19	19	18	18	18	18
Shares Outstanding (Diluted)	21	21	18	18	18	18
Shares Change (YoY)	16.86%	15.30%	-	-	-	-
EPS (Basic)	1.31	0.85	-0.91	-0.98	-0.84	-1.18
EPS (Diluted)	1.19	0.77	-0.91	-0.98	-0.84	-1.18
Free Cash Flow	24.53	-17.63	-10.15	-11.11	-11.47	-15.62
Free Cash Flow Per Share	1.15	-0.86	-0.57	-0.62	-0.64	-0.88
Gross Margin	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%
Operating Margin	58.78%	50.93%	-128.40%	-218.28%	-214.46%	-343.59%
Profit Margin	42.30%	30.83%	-179.13%	-287.05%	-258.61%	-399.35%
Free Cash Flow Margin	40.97%	-34.30%	-112.08%	-182.31%	-198.98%	-297.11%
EBITDA	35.21	26.2	-11.49	-13.27	-12.31	-17.99
EBITDA Margin	58.81%	50.98%	-126.89%	-217.67%	-213.64%	-
D&A For EBITDA	0.01	0.02	0.14	0.04	0.05	0.07
EBIT	35.2	26.17	-11.63	-13.3	-12.36	-18.07
EBIT Margin	58.78%	50.93%	-128.40%	-218.28%	-214.46%	-
Effective Tax Rate	17.98%	25.95%	-	-	-	-
Revenue as Reported	59.88	51.39	9.06	6.09	5.76	5.26

Updated Jun 30, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.